West Pharma (WST) – Major News
-
West Pharma (WST) Tops Q1 EPS by 26c, provides guidance
-
West Pharma (WST) Tops Q4 EPS by 5c, initiates FY 2024 guidance
-
West Pharma (WST) Tops Q3 EPS by 30c,offers guidance
-
West Pharma (WST) Tops Q2 EPS by 17c, offers guidance
-
West Pharma (WST) Tops Q1 EPS by 33c
-
West Pharma (WST) Tops Q4 EPS by 40c; Guides
-
West Pharma (WST) Misses Q3 EPS by 10c; Offers FY22 Revenue Guidance
-
West Pharma (WST) Tops Q2 EPS by 27c; Trims Outlook
-
West Pharma (WST) Tops Q1 EPS by 18c; Bumps Guidance Higher
-
West Pharma (WST) Tops Q4 EPS by 13c, Offers Guidance
-
West Pharma (WST) Tops Q3 EPS by 26c
-
West Pharma (WST) Tops Q2 EPS by 72c; Raises Outlook
-
West Pharma (WST) Tops Q1 EPS by 62c, Revenues Beat; Offers FY21 EPS/Revenues Guidance Above Consensus
-
West Pharma (WST) Tops Q4 EPS by 22c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus
-
West Pharma (WST) Tops Q3 EPS by 16c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
-
West Pharma (WST) Tops Q2 EPS by 34c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
-
West Pharma (WST) Tops Q1 EPS by 19c, Revenues Beat; Raises FY20 EPS Guidance Above Consensus, FY20 Revenue Outlook Above Consensus
-
West Pharma (WST) Tops Q4 EPS by 10c, Revenues Beat; Initiates FY20 EPS/Revenue Mid-Point Guidance Above Consensus
-
West Pharma (WST) Tops Q3 EPS by 8c, Revenues Beat; Raises FY19 EPS/Revenue Guidance Above Consensus
-
West Pharma (WST) Tops Q2 EPS by 17c, Revenues Beat; Raises FY19 EPS/Revenue Guidance
-
West Pharma (WST) Tops Q1 EPS by 9c, Revenues Beat; Raises FY19 EPS Guidance, Affirms FY19 Revenue Outlook
-
West Pharma (WST) Tops Q4 EPS by 1c, Revenues Miss; Offers FY19 EPS Guidance Below Consensus
-
West Pharma (WST) Tops Q3 EPS by 6c, Revenues Beat; Reaffirms FY18 EPS Mid-Point Guidance Above Consensus, Offers FY18 Revenue Outlook
-
West Pharma (WST) Tops Q2 EPS by 3c, Revenues Beat; Reaffirms FY Guidance
-
West Pharma (WST) Misses Q1 EPS by 2c, Beats on Revenues; Offers FY18 EPS/Revenue Mid-Point Outlooks Above Consenus
-
West Pharma (WST) Tops Q4 EPS by 1c, Slight Miss on Revenues
-
West Pharma (WST) Tops Q3 EPS by 14c, Beats on Revenues; Boosts FY17 EPS/Revenues Above Consensus
-
West Pharma (WST) Tops Q2 EPS by 1c; Lowers Top End of EPS Guidance
-
UPDATE: West Pharma (WST) Q1 EPS Tops Views; Reaffirms Guidance
-
West Pharma (WST) Misses Q4 EPS by 2c
-
West Pharma (WST) Reports In-Line Q3 EPS; Narrows EPS Outlook
-
West Pharma (WST) Tops Q2 EPS by 3c; Raises Outlook
-
West Pharma (WST) Tops Q1 EPS by 2c; Boosts Lower-End of FY16 Outlook
-
West Pharma (WST) Reports In-Line Q4 EPS, Offers FY Guidance
-
West Pharma (WST) Reports Q3 EPS of $0.44
-
West Pharma (WST) Tops Q2 EPS by 2c
-
West Pharma (WST) Tops Q1 EPS by 5c
-
West Pharma (WST) Appoints New CEO
-
West Pharma (WST) Misses Q4 EPS by 1c; Issues Light FY15 EPS Outlook
-
West Pharma (WST) Tops Q3 EPS by 1c; Trims FY Rev Outlook, Announces $100M Stock Buyback
-
West Pharma (WST) CEO Morel to Retire; Lowers FY14 EPS Midpoint
-
West Pharma (WST) Tops Q2 EPS by 5c
-
West Pharmaceutical Services, Inc. (WST) Misses Q1 EPS by 3c
-
West Pharma (WST) Reports In-Line Q4 EPS; Issues Lightish FY14 Profit Outlook
-
West Pharma (WST) Tops Q3 EPS by 4c; Boosts FY13 Outlook; Announces Stock Split
-
West Pharmaceutical Services, Inc. (WST) Tops Q1 EPS by 1c; Guides In-Line
-
West Pharmaceutical (WST) Tops Q4 EPS by 5c; Issues Strong FY13 Outlook
-
West Pharmaceutical Services, Inc. (WST) Tops Q3 EPS by 2c; Boosts FY12 EPS Outlook
-
West Pharmaceutical Services, Inc. (WST) Tops Q2 EPS by 10c
-
West Pharmaceutical Services, Inc. (WST) Tops Q1 EPS by 16c; Raises FY Guidance
Back to WST Stock Lookup